Value
-
Caught my eye — 9/13/24
Read more: Caught my eye — 9/13/24On the pile. 46Brooklyn put out a piece demonstrating the difficulty of understanding drug prices. It is a doozy of a read. A set-aside-time-to-concentrate read. But if you are skeptical about drug pricing and want to lump it all on manufacturers, you should take the time to read it. Big picture, there is no single…
-
340B, Biosimilars, Drug Prices, Generics, Healthcare Costs, Medicare Advantage, Medicare Part D, ValueCaught my eye — 6/21/24
Read more: Caught my eye — 6/21/24You know it is hot when I say, “Let’s go for a walk” and my dog looks at me from the stop of the stairs and refuses to move. At 6:30 in the morning. I hope you’re feeling more motivated than he is. Same same, not different. Late last year, the Medicare prescription drug benefit…
-
340B, Caught my eye, Drug Prices, Employers, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference Pricing, ValueCaught my eye — 5/10/24
Read more: Caught my eye — 5/10/24Back to back. Arnold Ventures put out the latest anti-pharma talking points (h/t Brian Reid) and here were two back to back – Here’s the problem, it really isn’t about the cost of drugs. I mean you could take that drug price and reduce it 98% and the 25% cost share would still be too…
-
Biosimilars, Caught my eye, Drug Prices, Healthcare Costs, Medicare Advantage, Medicare Part D, Pharmacy Benefit Managers, ValueCaught my eye — 2/9/24
Read more: Caught my eye — 2/9/24A whirlwind of a week. I regrouped on Wednesday and got a run in and some pottery wheel time and then it all fell apart again (in a good way) on Thursday where I forgot to leave my desk for hours and hours. One of those “I love working” and forget time exists. So much…
-
Required Reading: Come on Down
Read more: Required Reading: Come on DownIt is rare for me to print things anymore; limited access to a giant corporate printer cuts down on the urge. But today I got the printer going, grabbed the highlighter and dug in. The paper? “Is the price right? Paying for value today to get more value tomorrow.” If I were a health policy…
-
Caught my eye — 11/3/23
Read more: Caught my eye — 11/3/23InNOvation. Seagen said they aren’t looking at a drug that would treat early-stage bladder cancer because it would be subject to negotiation too soon after approval and wouldn’t have a financial return on the investment. Today the National Pharmaceutical Council published a great piece in Health Affairs that goes deeper into the subject of innovation…
-
What is Value Anyway?
Read more: What is Value Anyway?A few weeks ago I watched novelist John Green get emotional in a YouTube video about the price of a tuberculosis test by Cepheid. The gist is that the TB test costs $10 while (likely) costing less than $5 to produce. There is acknowledgement that the product is “incredible, amazing, wonderous.” But it should be…
Latest news
- Caught my eye — 11/15/24
- Caught my eye — 11/8/24
- Caught my eye — 11/1/24
- Caught my eye — 10/25/24
- Caught my eye — 10/18/24
Categories
- 340B (26)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (18)
- Caught my eye (46)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (23)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (3)
- Health Equity (3)
- Healthcare Costs (21)
- ICER (5)
- Importation (2)
- Inflation Reduction Act (39)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (12)
- Medicare Negotiation (40)
- Medicare Part D (35)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (23)
- Reference Pricing (3)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (7)